Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress
Portfolio Pulse from
Karyopharm reported $145 million in total revenue for 2024, with $113 million from U.S. XPOVIO® sales. The company anticipates top-line data from the Phase 3 SENTRY trial in 2H 2025 and updated its Phase 3 XPORT-EC-042 trial to focus on specific patient groups after discussions with the FDA.
February 19, 2025 | 12:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Karyopharm's 2024 financial results show strong revenue from XPOVIO®. The company is progressing with its clinical trials, including the SENTRY trial and an updated focus for the XPORT-EC-042 trial after FDA discussions.
The financial results indicate strong performance, particularly from XPOVIO®. The updates on clinical trials, especially the refocus of the XPORT-EC-042 trial after FDA discussions, suggest proactive management and potential future growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100